Hypothyroidism – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Hypothyroidism – Pipeline Review, H2 2016’, provides an overview of the Hypothyroidism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypothyroidism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypothyroidism and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Hypothyroidism

The report reviews pipeline therapeutics for Hypothyroidism by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Hypothyroidism therapeutics and enlists all their major and minor projects

The report assesses Hypothyroidism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Hypothyroidism

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Hypothyroidism

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hypothyroidism pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Synthonics Inc

Titan Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Hypothyroidism Overview 6

Therapeutics Development 7

Pipeline Products for Hypothyroidism - Overview 7

Hypothyroidism - Therapeutics under Development by Companies 8

Hypothyroidism - Pipeline Products Glance 9

Late Stage Products 9

Early Stage Products 10

Hypothyroidism - Products under Development by Companies 11

Hypothyroidism - Companies Involved in Therapeutics Development 12

Synthonics Inc 12

Titan Pharmaceuticals Inc 13

Hypothyroidism - Therapeutics Assessment 14

Assessment by Monotherapy Products 14

Assessment by Combination Products 15

Assessment by Target 16

Assessment by Mechanism of Action 17

Assessment by Route of Administration 18

Assessment by Molecule Type 20

Drug Profiles 21

(levothyroxine + liothyronine) - Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

BCT-305 - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

levothyroxine sodium SR - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

liothyronine - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

liothyronine sodium - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

liothyronine sodium SR - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

Hypothyroidism - Dormant Projects 27

Appendix 28

Methodology 28

Coverage 28

Secondary Research 28

Primary Research 28

Expert Panel Validation 28

Contact Us 28

Disclaimer 29

List of Tables

List of Tables

Number of Products under Development for Hypothyroidism, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Late Stage Development, H2 2016 9

Comparative Analysis by Early Stage Development, H2 2016 10

Products under Development by Companies, H2 2016 11

Hypothyroidism – Pipeline by Synthonics Inc, H2 2016 12

Hypothyroidism – Pipeline by Titan Pharmaceuticals Inc, H2 2016 13

Assessment by Monotherapy Products, H2 2016 14

Assessment by Combination Products, H2 2016 15

Number of Products by Stage and Target, H2 2016 16

Number of Products by Stage and Mechanism of Action, H2 2016 17

Number of Products by Stage and Route of Administration, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 20

Hypothyroidism – Dormant Projects, H2 2016 27

List of Figures

List of Figures

Number of Products under Development for Hypothyroidism, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Assessment by Monotherapy Products, H2 2016 14

Number of Products by Stage and Targets, H2 2016 16

Number of Products by Stage and Mechanism of Actions, H2 2016 17

Number of Products by Routes of Administration, H2 2016 18

Number of Products by Stage and Routes of Administration, H2 2016 18

Number of Products by Stage and Molecule Types, H2 2016 20

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports